Podcasts

Articles

Webinars

Peer-Reviewed

Videos

ASCO: American Society of Clinical Oncology

A multidisciplinary team of oncologists, health care providers, caregivers, and the patients themselves benefits everyone, and telehealth-based interventions can help to foster these relationships, but we should understand when patients do not want to involve their families in their care, noted Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing and associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University in Cleveland, Ohio.

Dr Sara Douglas: Video Conference Interventions Are an Invaluable Resource for Those Who Choose to Participate

Blocking TIGIT, a T-cell immunoreceptor, benefits patients with non–small lung cancer in that it can restore their immune system’s antitumor response, leading to a greater objective response and progression-free survival, noted Melissa L. Johnson, MD, associate director for Lung Cancer Research at Sarah Cannon Research Institute and partner in Tennessee Oncology, discussing the results of the CITYSCAPE trial.
 

Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response in CITYSCAPE Trial

Coronavirus disease 2019 disparities persist in our most vulnerable communities because of the financial necessity to continue working, as well as the lack of employment opportunities that enable their residents to work remotely. They are more likely to be considered essential workers, and that increases their exposure to the virus, explained Blythe Adamson, PhD, MPH, principal quantitative scientist at Flatiron Health.

Protecting the Health of Our Most Vulnerable Populations Means Understanding Their Motivations

Getting the full picture of genetic testing results requires that patients have access to genetic counselors who can evaluate individual risk.

Genetic Testing Can Guide Treatment, but Access and Counseling Are Essential, Studies Say

A picture is emerging picture of what patients with cancer face under coronavirus disease 2019 (COVID-19): They are more likely to be older or have underlying health problems, which are known to make the virus more deadly. But the treatments that can stop cancer could also put that at risk.

NCI's Sharpless: COVID-19 Could Halt Streak of US Cancer Mortality Gains

Compared with ibrutinib, zanubrutinib appears to have more of a benefit for patients with regards to less atrial fibrillation, hypertension, and other cardiac effects, explained Constantine S. Tam, MBBS, MD, clinical hematologist, Peter MacCallum Cancer Centre in Melbourne, Australia.

Dr Constantine Tam Discusses the Benefits of Zanubrutinib on Cardiac Effects

Telemedicine has grown from about 10% of all patient visits, before the coronavirus disease 2019 pandemic, to almost 90% at present, and it isn’t going away anytime soon, noted Sara L. Douglas, PhD, RN, the Gertrude Perkins Oliva Professor in Oncology Nursing and associate dean for research at the Frances Payne Bolton School of Nursing at Case Western Reserve University in Cleveland, Ohio.
 

In-person Visits Are Invaluable, but Telehealth Is Here to Stay

"Our patients are the reasons we do what we do. They are the reason we do the work," said outgoing ASCO President Howard A. “Skip” Burris III, MD, FASCO, FACP, during his opening address on the second day of this year’s American Society of Clinical Oncology conference.

Burris: United With Our Patients, We Do Accelerate Progress Together

Zanubrutinib, a second-generation BTK inhibitor, is approved by FDA to treat mantle cell lymphoma.

Zanubrutinib Pulls Away From Ibrutinib in Update, Shows Durable Responses in Waldenstrom Patients Lacking Key Mutation

An experimental glioblastoma therapy with promising 12-month results may also have potential with other treatment-resistant cancers, according to Jeffrey Skolnick, MD, vice president, clinical development, Inovio Pharmaceuticals Inc. Results are being presented during the American Society of Clinical Oncology 2020 annual meeting.